Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  BioMérieux    BIM   FR0013280286

BIOMÉRIEUX

(BIM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/18/2020 11/19/2020 11/20/2020 11/23/2020 11/24/2020 Date
119.6(c) 119.4(c) 117.8(c) 116.9(c) 112.7 Last
122 972 162 443 161 604 127 413 80 488 Volume
-3.08% -0.17% -1.34% -0.76% -3.59% Change
More quotes
Financials
Sales 2020 3 133 M 3 724 M 3 724 M
Net income 2020 376 M 447 M 447 M
Net Debt 2020 102 M 121 M 121 M
P/E ratio 2020 36,9x
Yield 2020 0,36%
Sales 2021 3 321 M 3 947 M 3 947 M
Net income 2021 399 M 474 M 474 M
Net cash position 2021 128 M 152 M 152 M
P/E ratio 2021 34,7x
Yield 2021 0,42%
Capitalization 13 835 M 16 343 M 16 445 M
EV / Sales 2020 4,45x
EV / Sales 2021 4,13x
Nbr of Employees 12 000
Free-Float 31,2%
More Financials
Company
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (82.5%): in industry, microbiological testing of samples from... 
More about the company
Notations Surperformance© of bioMérieux
Trading Rating : Investor Rating :
More Ratings
All news about BIOMÉRIEUX
11/19BIOMERIEUX : bioMérieux announces the expansion of the CE marking of its molecul..
PU
11/16BIOMÉRIEUX : Announces the Expansion of the CE Marking of Its Molecular Biology ..
BU
11/16BIOMERIEUX : bioMérieux announces the expansion of the CE marking of its molecul..
PU
10/22BIOMÉRIEUX : – Third-Quarter 2020 Business Review
BU
10/09BIOMERIEUX : Annual Report 2019
PU
10/08BIOMERIEUX : AMSP partners with bioMérieux to facilitate supply of high-quality ..
PU
10/06ABBOTT LABORATORIES : Canada to Buy Up to 20.5 Million of Abbott's Panbio Covid-..
DJ
09/10BIOMERIEUX : Interim Financial Report 2020
PU
09/02BIOMÉRIEUX : – First-Half 2020 Results
BU
09/01MERIEUX NUTRISCIENCES : ' EnviroMap Collaborates with BIOMERIEUX, Inc.
PR
08/28BIOMÉRIEUX : half-yearly earnings release
07/16BIOMERIEUX : Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biop..
PU
07/16BIOMÉRIEUX : Launch of BIOFIRE® MYCOPLASMA Test for Mycoplasma Detection in Biop..
BU
07/15BIOMERIEUX : BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
BU
07/14BIOMÉRIEUX : Ex-dividend day for final dividend
FA
More news
News in other languages on BIOMÉRIEUX
11/17AVIS D'ANALYSTES DU JOUR : Crédit Agricole, Dufry, Edenred, Faurecia, Natixis, S..
11/16BIOMERIEUX : extension aux échantillons salivaires du marquage CE de son test Co..
11/16BIOMÉRIEUX : extension du marquage CE pour le test Argene
11/16COVID, CROISSANCE, STRATÉGIE : à la croisée des chemins
11/16BIOMÉRIEUX : annonce l'extension aux échantillons salivaires du marquage CE de s..
More news
Analyst Recommendations on BIOMÉRIEUX
More recommendations
Stock Trading Strategies
BIOMÉRIEUX - 09/08
A support level that should be taken advantage of
BUY
More Stock Trading Analysis
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | BIM | FR0013280286 | MarketScreener
Technical analysis trends BIOMÉRIEUX
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 123,44 €
Last Close Price 116,90 €
Spread / Highest target 31,7%
Spread / Average Target 5,59%
Spread / Lowest Target -42,7%
EPS Revisions
Managers
NameTitle
Alexandre Mérieux Chairman & Chief Executive Officer
Alain Mérieux Founding Chairman
Guillaume Bouhours EVP-Finance, Purchasing & Information Systems
François Lacoste Executive Director-Research & Development
Mark Miller Executive Director-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BIOMÉRIEUX47.32%16 343
10X GENOMICS, INC.83.24%15 035
DIASORIN S.P.A.50.52%11 249
AUTOBIO DIAGNOSTICS CO., LTD.63.90%10 725
NATERA, INC.155.24%7 291
MACCURA BIOTECHNOLOGY CO.LTD67.67%3 780